96 Tests PN: B511131

Components:

45x Ab-conjugated beads (S5P4 - Canine TNFα Ab-bead). PN: B511131A. One vial containing 100 µL of anti-canine TNFα conjugated to AimPlex Bead S5P4.

25x Biotin-detection Ab (Canine TNFα Biotin-dAb). PN: B511131B. One vial containing 100 µL of biotinylated anti-canine TNFα.

Lyophilized Standard Mix-Canine Group 1 Panel A, 10-Plex. PN: KG10010. One vial containing lyophilized recombinant IFNγ, IL-2, IL-6, IL-8, IL-10, IL-12p40, IL-17A, MCP-1, SCF and TNFα. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

Application: Optimal antibody pair and antigen standard for assaying CanineTNFα.  Can be multiplexed with other analytes in Canine Group 1.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 2 pg/mL

  • Quantitation range:

  • LLOQ: < 5 pg/mL

  • ULOQ: > 2,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Canine Group 1: Negligible

  • Sample volume: 15 µL/test

Description:

Tumor Necrosis Factor alpha (Accession P51742) is a member of the TNF Superfamily. TNF-α is produced by a variety of leukocytes, though mostly by activated macrophages. As an immune cell regulator with many roles, TNF-α may also induce fever, apoptosis or necrosis. Abnormal TNF-α production has been correlated to major depression, Alzheimer’s disease, cancer, psoriasis, and inflammatory bowel disease. TNF-α is also associated with insulin resistance, due to its over expression in adipose tissue in obese rodents and humans. Tumor necrosis factor alpha, additionally, has links to the pathologies of neuropathic pain and a compounding effect on malignancy-associated hypercalcemia with parathyroid hormone-related protein.

References:

  1. Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc. Res. Tech. 2000. 1;50(3): 184-95. Doi: 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H.

  2. Wagner R, Myers RR. Endoneurial injection of TNF-alpha produces neuropathic pain behaviors. Neuro Report. 1996; 7(18): 2897-2901. Doi: 10.1097/00001756-199611250-00018.

  3. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNF alpha by human muscle. Relationship to insulin resistance. JCI. 1996; 2 (97): 1111-1116. Doi: 10.1172/JCI118504.

  4. Uy HL, Mundy GR, Boyce BF, Story BM, Dunstan CR, Yin JJ, Roodman GD, Guise TA. Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. Cancer Res. 1997; 57(15): 3194-3199. PMID: 9242449.